Tilia Fiduciary Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-9,189
| Closed | -$1.9M | – | 106 |
|
|
2024
Q2 | $1.9M | Buy |
9,189
+663
| +8% | +$137K | 1.48% | 28 |
|
|
2024
Q1 | $2.31M | Buy |
8,526
+914
| +12% | +$248K | 1.87% | 12 |
|
|
2023
Q4 | $1.8M | Buy |
7,612
+1,317
| +21% | +$311K | 1.67% | 17 |
|
|
2023
Q3 | $1.23M | Buy |
6,295
+545
| +9% | +$107K | 1.28% | 33 |
|
|
2023
Q2 | $1.21M | Buy |
5,750
+837
| +17% | +$176K | 1.08% | 33 |
|
|
2023
Q1 | $992K | Buy |
4,913
+221
| +5% | +$44.6K | 0.95% | 36 |
|
|
2022
Q4 | $1.02M | Buy |
4,692
+104
| +2% | +$22.7K | 0.98% | 32 |
|
|
2022
Q3 | $904K | Buy |
4,588
+474
| +12% | +$93.4K | 0.91% | 35 |
|
|
2022
Q2 | $895K | Buy |
4,114
+259
| +7% | +$56.3K | 0.85% | 40 |
|
|
2022
Q1 | $1.1M | Buy |
3,855
+265
| +7% | +$75.3K | 0.93% | 38 |
|
|
2021
Q4 | $1.35M | Buy |
+3,590
| New | +$1.35M | 1.09% | 24 |
|